loader from loading.io

Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

Speaking of SurgOnc

Release Date: 11/14/2023

Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? show art Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?

Speaking of SurgOnc

Rick Greene, MD, discusses with Patricio M. Polanco, MD, an analysis of three hospital designations, as well as volume status, and their effect on the delivery of care and survival outcomes using a cancer registry database of the second largest state in the USA. Dr. Polanco is co-corresponding author of, “Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?.”

info_outline
Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study show art Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study

Speaking of SurgOnc

Rick Greene, MD, discusses with Eduardo A. Vega, MD, definitions reported on of benchmark values for gallbladder cancer surgery across an international population as well as geographic differences in gallbladder cancer surgery across multiple continents. Dr. Vega is the senior author of, “Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.” Dr. Vega is Assistant Professor of Surgery at Boston University School of Medicine and Hepato-Bilio-Pancreatic surgeon in the Department of Surgery at St. Elizabeth’s Medical Center, Boston, MA....

info_outline
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer show art CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Speaking of SurgOnc

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.” Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University...

info_outline
Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients show art Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

Speaking of SurgOnc

Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.” Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada.

info_outline
Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects show art Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects

Speaking of SurgOnc

Rick Greene, MD, discusses with Anna Weiss, MD, the evidence-based treatments available for the adverse effects of endocrine therapy that can be experienced by breast cancer patients, including clear treatment algorithms for genitourinary syndrome of menopause (GSM), which can be overlooked by providers. Dr. Weiss is the senior author of, “Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.” Dr. Weiss is Associate Professor of Surgery and Medicine, and Director of the Wilmot Cancer Institute Comprehensive Breast Cancer Program at...

info_outline
Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer show art Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer

Speaking of SurgOnc

Rick Greene, MD, and Tari King, MD, FSSO, discuss findings generated from central path review of a large series of patients treated with neoadjuvant chemotherapy and surgery regarding the pattern of residual tumor in the breast and its related prognostic significance. Dr. King is the senior author of, “Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer.” Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the vice chair...

info_outline
Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center show art Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center

Speaking of SurgOnc

Rick Greene, MD discusses with Edward A. Levine, MD, long-term survival in patients with malignant peritoneal mesothelioma undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dr. Levine is the senior author of, “Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.” Dr. Levine is Professor, Surgical Sciences - Oncology, Chief of Surgical Oncology at Atrium Wake Forest Health, and Section Editor of the Peritoneal Surface Malignancies section of the Annals of...

info_outline
Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT show art Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT

Speaking of SurgOnc

Rick Greene, MD, discusses with Jesse Selber MD, MPH, MHCM, FACS, the use of ChatGPT and explores questions regarding the potential of artificial intelligence (AI) in surgery and its opportunities, challenges, and possible role in surgery. Dr. Selber is the senior author of the article entitled "Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT.” Dr. Selber is Surgical Service Line Chief and Professor of Plastic Surgery at Corewell Health, East outside of Detroit, Michigan.

info_outline
A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases show art A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases

Speaking of SurgOnc

Rick Greene, MD, discusses with Giammauro Berardi, MD, PhD, FEBS, the outcomes of a large cohort of patients undergoing upfront surgery for resectable colorectal liver metastases (CRLM) to analyze the predictability and probability of early treatment failure using clinicopathological characteristics. Dr. Berardi is author of,  Dr. Berardi is attending at the Department of HPB Surgery and Liver Transplantation of the San Camillo Forlanini Hospital, Rome, Italy, and previous to that was a Surgical Oncology clinical fellow at Memorial Sloan-Kettering Cancer Center, New York NY.

info_outline
Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients show art Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients

Speaking of SurgOnc

Rick Greene, MD, discusses with Julie Culver, MS, LCGC, CCRP,  the implementation of genetic testing for all patients with breast cancer and how this can be incorporated into oncology care. Ms. Culver is author of Julie Culver is the Director of Genetic Counseling at the USC Norris Cancer Hospital and is a Clinical Instructor of Medicine at the USC Keck School of Medicine, Los Angeles, CA. http://doi.org/10.1245/S10434-022-12595-W

info_outline
 
More Episodes

Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.”

Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada.